Delivery Order SPE2DB22D3401-SPE2DB25FT5RB
- Not listed
- This is a federal contract award made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,931.53, is for the delivery of ANDEXXA 200 MG VIALS and has an ultimate completion date of April 2, 2025. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running...
- This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for ANDEXXA 200 MG VIALS. The $20,794.59 firm fixed price contract has a completion date of July 21, 2025. Amerisourcebergen Drug Corp is the prime contractor, and there is no set-aside designation for this award. This delivery order is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- The U.S. government has awarded a delivery order contract worth $15,050.28 to Amerisourcebergen Drug Corp's Corporate Office Division to provide the pharmaceutical product ANDEXXA 200 MG VIALS. This contract has no set-aside designation and is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. Under this IDC, Amerisourcebergen supplies a comprehensive range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office Division for the delivery of 4564433758 ANDEXXA 200 MG VIALS. The contract has a firm fixed price ceiling value of $33,293.65 and a completion date of May 20, 2024. This is a delivery order contract type with no set-aside designation. AmerisourceBergen, a major pharmaceutical distribution company, has been awarded this order as part of its Indefinite Delivery...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $79,161.66 firm fixed-price delivery order is for the supply of ANDEXXA 200 MG VIALS. The contract has an ultimate completion date of November 18, 2022 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation, is a delivery order valued at $16,783.10 for the supply of ANDEXXA 200 MG VIALS. The contract is a firm fixed price award issued by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the U.S. Department of Defense. Amerisourcebergen Drug Corp is the prime contractor and this award is not associated with any set-aside designation....
- The U.S. federal government awarded a delivery order contract valued at $6,658.72 to Amerisourcebergen Drug Corp's Corporate Office Division. The contract, awarded by the Defense Logistics Agency (DLA) Troop Support Medical, is for the supply of ANDEXXA 200 MG VIALS, a pharmaceutical product. This contract is not set aside for any particular business type. Amerisourcebergen is a major pharmaceutical distributor that holds several Indefinite Delivery Contracts (IDCs) with federal agencies,...
- The Defense Logistics Agency Troop Support Medical awarded a $12,500 firm fixed price delivery order to Amerisourcebergen Drug Corp Corporate Office Division for 200 mg vials of ANDEXXA. The place of performance is Conshohocken, Pennsylvania. The delivery order has a period of performance from July 25, 2023 through August 15, 2023. No major subcontractors or set aside designations were indicated. The Defense Logistics Agency supports Department of Defense health care programs through its medical...
- This federal contract award is for the delivery of ANDEXXA 200 MG VIALS to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense (DoD). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, and has a ceiling value of $8,391.55. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA, valued up to $999,999,999.00 through December 31, 2025. This...
- The Defense Logistics Agency awarded a $2,910.13 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tranexamic 1,000 mg/100 mL-NaCl 100 mL, a hemostatic agent commonly used in military and medical settings to reduce bleeding. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT5RBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $17,344.30 to AmerisourceBergen Drug Corp for the supply of Andexxa 200 mg vials. This competitively awarded, firm fixed price delivery order is scheduled for completion by September 4, 2025, with performance occurring at the vendor's Conshohocken, Pennsylvania location. The contract utilizes no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete for federal medical procurement requirements. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. Andexxa is a specialized reversal agent used in emergency medical situations, reflecting the company's critical role in providing specialized pharmaceutical commodities to support military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.3k | 8/13/25 |